Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5563_Библиотеки_им_академика_М_И_Перельмана.pdf
66 The Dynamics of Tumor Microenvironment and Therapeutic Targets
42. Nair N, Calle AS, Zahra MH, Prieto-Vila M, Oo AKK, Hurley L, et al. A cancer stem
cell model as the point of origin of cancer-associated broblasts in tumor microenviron-
ment. Sci Rep. 2017;7:6838.
43. Yin C, Evason KJ, Asahina K, Stainier DYR. Hepatic stellate cells in liver develop-
ment, regeneration, and cancer. J Clin Invest. 2013;123:1902–1910.
44. Omary MB, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: Astar on the
rise in pancreatic diseases. J Clin Invest. 2007;117:50–59.
45. Ezhilarasan D. Hepatic stellate cells in the injured liver: Perspectives beyond hepatic
brosis. J Cell Physiol. 2022;237:436–449.
46. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, et al. Pancreatic stel-
late cells: Partners in crime with pancreatic cancer cells. Cancer Res. 2008;68:
2085–2093.
47. Schoepp M, Ströse AJ, Haier J. Dysregulation of miRNA expression in cancer associ-
ated broblasts (CAFs) and its consequences on the tumor microenvironment. Cancers
(Basel). 2017;9:54.
48. Helms EJ, Berry MW, Chaw RC, DuFort CC, Sun D, Onate MK, et al. Mesenchymal lin-
eage heterogeneity underlies nonredundant functions of pancreatic cancer–associated
broblasts. Cancer Discov. 2022;12:484–501.
49. Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al.
Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myobro-
blasts as a determinant of patient response to cancer immunotherapy. Cancer Discov.
2020;10:232–253.
50. Kobayashi H, Gieniec KA, Lannagan TRM, Wang T, Asai N, Mizutani Y, et al. The
origin and contribution of cancer-associated broblasts in colorectal carcinogenesis.
Gastroenterology. 2022;162:890–906.
51. Bartoschek M, Oskolkov N, Bocci M, Lövrot J, Larsson C, Sommarin M, et al. Spatially
and functionally distinct subclasses of breast cancer-associated broblasts revealed by
single cell RNA sequencing. Nat Commun. 2018;9:5150.
52. Plikus MV, Wang X, Sinha S, Forte E, Thompson SM, Herzog EL, et al. Fibroblasts:
Origins, denitions, and functions in health and disease. Cell. 2021;184:3852–3872.
53. Garcia PE, Adoumie M, Kim EC, Zhang Y, Scales MK, El-Tawil YS, et al. Differential
contribution of pancreatic broblast subsets to the pancreatic cancer stroma. Cell Mol
Gastro
enterol Hepatol. 2020;10:581–599.
54. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to
mesenchymal transition as a source for carcinoma-associated broblasts. Cancer Res.
20 07;67:10123–10128.
55. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that broblasts
derive from epithelium during tissue brosis. J Clin Invest. 2002;110:341–350.
56. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.
57. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal
stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;
449:557–563.
58. Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, et al. Cancer-associated
adipocytes exhibit an activated phenotype and contribute to breast cancer invasion.
Cancer Res. 2011;71:2455–2465.
59. Bochet L, Lehuédé C, Dauvillier S, Wang YY, Dirat B, Laurent V, et al. Adipocyte-
derived broblasts promote tumor progression and contribute to the desmoplastic reac-
tion in breast cancer. Cancer Res. 2013;73:5657–5668.
60. Mastrogiannaki M, Lichtenberger BM, Reimer A, Collins CA, Driskell RR, Watt
FM. β-Catenin stabilization in skin broblasts causes brotic lesions by prevent-
ing adipocyte differentiation of the reticular dermis. J Invest Dermatol. 2016;136:
1130–1142.
67Cancer-Associated Fibroblasts and Glioblastoma
61. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR,
et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor
growth. Nat Med. 2011;17:1498–1503.
62. Tang PC, Chung JY, Xue VW, Xiao J, Meng X, Huang X, et al. Smad3 promotes cancer-
associated broblasts generation via macrophage–myobroblast transition. Adv Sci.
2022;9:2101235.
63. Tang PM-K, Zhang Y, Xiao J, Tang PC-T, Chung JY-F, Li J, et al. Neural transcription
factor Pou4f1 promotes renal brosis via macrophage–myobroblast transition. Proc
Natl Acad Sci. 2020;117:20741–20752.
64. Hosaka K, Yang Y, Seki T, Fischer C, Dubey O, Fredlund E, et al. Pericyte–
broblast transition promotes tumor growth and metastasis. Proc Natl Acad Sci. 2016;
113:E5618–E5627.
65. Rynne-Vidal A, Jiménez-Heffernan JA, Fernández-Chacón C, López-Cabrera M,
Sandoval P. The mesothelial origin of carcinoma associated-broblasts in peritoneal
metastasis. Cancers (Basel). 2015;7:1994–2011.
66. McAnulty RJ. Fibroblasts and myobroblasts: Their source, function and role in dis-
ease. Int J Biochem Cell Biol. 2007;39:666–671.
67. Neuzillet C, Tijeras-Raballand A, Ragulan C, Cros J, Patil Y, Martinet M, et al. Inter-
and intra-tumoural heterogeneity in cancer-associated broblasts of human pancreatic
ductal adenocarcinoma. J Pathol. 2019;248:51–65.
68. Peltier A, Seban R-D, Buvat I, Bidard F-C, Mechta-Grigoriou F. Fibroblast heterogene-
ity in solid tumors: From single cell analysis to whole-body imaging. Semin Cancer
Biol. 2022;86:262–272, Elsevier.
69. Han C, Liu T, Yin R. Biomarkers for cancer-associated broblasts. Biomark Res.
2020;8:1–8.
70. Calvete J, Larrinaga G, Errarte P, Martin AM, Dotor A, Esquinas C, et al. The coex-
pression of broblast activation protein (FAP) and basal-type markers (CK 5/6 and
CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Hum Pathol. 2019;91:61–68.
71. An J, Hou D, Wang L, Wang L, Yang Y, Wang H. Fibroblast activation protein-alpha
knockdown suppresses prostate cancer cell invasion and proliferation. 2022;37(6):597–
60 7. doi:10.14670/HH-18-430.
72. Gong C, Nie Y, Qu S, Liao J-Y, Cui X, Yao H, et al. miR-21 induces myobroblast dif-
ferentiation and promotes the malignant progression of breast phyllodes tumors. Cancer
Res. 2014;74:4341–4352.
73. Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, et al. Single-cell and spatial analysis
reveal interaction of FAP+ broblasts and SPP1+ macrophages in colorectal cancer. Nat
Commun. 2
022;13:1742.
74. Wen X, He X, Jiao F, Wang C, Sun Y, Ren X, et al. Fibroblast activation protein-α-
positive broblasts promote gastric cancer progression and resistance to immune
checkpoint blockade. Oncol Res. 2017;25:629.
75. Rong X, Lv J, Liu Y, Wang Z, Zeng D, Li Y, et al. PET/CT imaging of activated can-
cer-associated broblasts predict response to PD-1 blockade in gastric cancer patients.
Front Oncol. 2022;11:802257.
76. Lin Y, Li B, Yang X, Cai Q, Liu W, Tian M, et al. Fibroblastic FAP promotes intrahepatic
cholangiocarcinoma growth via MDSCs recruitment. Neoplasia. 2019;21:1133–1142.
77. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast
heterogeneity and immunosuppressive environment in human breast cancer. Cancer
Cell. 2018;33:463–479.
78. Scott AM, Wiseman G, Welt S, Adjei A, Lee F-T, Hopkins W, et al. A phase Idose-
escalation study of sibrotuzumab in patients with advanced or metastatic broblast acti-
vation protein-positive cancer. Clin Cancer Res. 2003;9:1639–1647.
68 The Dynamics of Tumor Microenvironment and Therapeutic Targets
79. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, et al. Antibody
targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19
against a cell-surface protein of reactive tumor stromal broblasts. J Clin Oncol.
1994;12:1193–1203.
80. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al.
Suppression of antitumor immunity by stromal cells expressing broblast activation
protein
–α. Science (80–). 2010;330:827–830.
81. Santos AM, Jung J, Aziz N, Kissil JL, Puré E. Targeting broblast activation protein
inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009;119:3613–3625.
82. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small
molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and aug-
ments an
tibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res.
2004;64:5471–5480.
83. Loefer M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated
broblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J
Clin Invest. 2006;116:1955–1962.
84. Mezawa Y, Orimo A. The roles of tumor-and metastasis-promoting carcinoma-associated
broblasts in human carcinomas. Cell Tissue Res. 2016;365:675–689.
85. Bu L, Baba H, Yoshida N, Miyake K, Yasuda T, Uchihara T, et al. Biological hetero-
geneity and versatility of cancer-associated broblasts in the tumor microenvironment.
Oncogene. 2019;38:4887–4901.
86. Madar S, Goldstein I, Rotter V. “Cancer associated broblasts”—more than meets the
eye. Trends Mol Med. 2013;19:447–453.
87. Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MAC, et al. Osteopontin
mediates an MZF1–TGF-β1-dependent transformation of mesenchymal stem cells into
cancer-associated broblasts in breast cancer. Oncogene. 2015;34:4821–4833.
88. Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, Kayashima T, et al. α-Smooth
muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic
ductal adenocarcinoma. Pancreas. 2010;39:1254–1262.
89. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-
smooth muscle actin-positive broblasts promote biliary cell proliferation and correlate
with poor survival in cholangiocarcinoma. Oncol Rep. 2009;21:957–969.
90. Grout JA, Sirven P, Leader AM, Maskey S, Hector E, Puisieux I, et al. Spatial position-
ing and matrix programs of cancer-associated broblasts promote T-cell exclusion in
human lung tumors. Cancer Discov. 2022;12:2606–2625.
91. Okuyama K, Suzuki K, Yanamoto S, Naruse T, Tsuchihashi H, Yamashita S, et al.
Anaplastic transition within the cancer microenvironment in early-stage oral tongue
squamo
us cell carcinoma is associated with local recurrence. Int J Oncol. 2018;
53:1713–1720.
92. Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, et al. A subset of myo-
broblastic cancer-associated broblasts regulate collagen ber elongation, which is
prognostic in multiple cancers. Oncotarget. 2016;7:6159.
93. Ni W-D, Yang Z-T, Cui C-A, Cui Y, Fang L-Y, Xuan Y-H. Tenascin-C is a potential
cancer-associated broblasts marker and predicts poor prognosis in prostate cancer.
Biochem Biophys Res Commun. 2017;486:607–612.
94. Muchlińska A, Nagel A, Popęda M, Szade J, Niemira M, Zieliński J, et al. Alpha-
smooth muscle actin-positive cancer-associated broblasts secreting osteopontin pro-
mote growth of luminal breast cancer. Cell Mol Biol Lett. 2022;27:45.
95. Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle J-C, et al. Identication
of prognostic molecular features in the reactive stroma of human breast and prostate
cancer. PLoS One. 2011;6:e18640.
69Cancer-Associated Fibroblasts and Glioblastoma
96. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, et al. Periostin potently promotes
metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB path-
way. Canc
er Cell. 2004;5:329–339.
97. Kikuchi Y, Kunita A, Iwata C, Komura D, Nishiyama T, Shimazu K, et al. The niche
component periostin is produced by cancer-associated broblasts, supporting growth of
gastric cancer through ERK activation. Am J Pathol. 2014;184:859–870.
98. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted
by epithelial ovarian carcinoma is a ligand for αVβ3 and αVβ5 integrins and promotes
cell motility. Cancer Res. 2002;62:5358–5364.
99. Yue H, Li W, Chen R, Wang J, Lu X, Li J. Stromal POSTN induced by TGF-β1
facilitates the migration and invasion of ovarian cancer. Gynecol Oncol. 2021;160:
530–538.
100. Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, et al. Cancer-
associated broblasts predict poor outcome and promote periostin-dependent invasion
in oesophageal adenocarcinoma. J Pathol. 2015;235:466–477.
101. Li X, Sun Z, Peng G, Xiao Y, Guo J, Wu B, et al. Single-cell RNA sequencing reveals
a pro-invasive cancer-associated broblast subgroup associated with poor clinical out-
comes in patients with gastric cancer. Theranostics. 2022;12:620.
102. Lee YJ, Kim IS, Park S-A, Kim Y, Lee JE, Noh D-Y, et al. Periostin-binding DNA
aptamer inhibits breast cancer growth and metastasis. Mol Ther. 2013;21:1004–1013.
103. Deng X, Ao S, Hou J, Li Z, Lei Y, Lyu G. Prognostic signicance of periostin in
colorectal cancer. Chinese J Cancer Res. 2019;31:547.
104. Liu T, Zhou L, Xiao Y, Andl T, Zhang Y. BRAF inhibitors reprogram cancer-associated
broblasts to drive matrix remodeling and therapeutic escape in melanoma. Cancer
Res. 2022;82:419–432.
105. Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, et al. Upregulation of periostin
and reactive stroma is associated with primary chemoresistance and predicts clinical
outcomes in epithelial ovarian cancer. Clin Cancer Res. 2015;21:2941–2951.
106. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W,
et al. Prognostic signicance of epithelial-mesenchymal and mesenchymal-epithelial
transition protein expression in non–small cell lung cancer. Clin Cancer Res.
2008;14:7430 –7437.
107. Neuzillet C, Nicolle R, Raffenne J, Tijeras-Raballand A, Brunel A, Astorgues-Xerri L,
et al. Periostin- and podoplanin-positive cancer-associated broblast subtypes cooper-
ate to shape the inamed tumor microenvironment in aggressive pancreatic adenocar-
cinoma. J Pathol. 2022;258:408–425.
108. Insua-Rodríguez J, Oskarsson T. The extracellular matrix in breast cancer. Adv Drug
Deliv Rev. 2016;97:41–55.
109. Primac I, Maquoi E, Blacher S, Heljasvaara R, Van Deun J, Smeland HYH, et al.
Stromal integrin α11 regulates PDGFRβ signaling and promotes breast cancer progres-
sion. J Clin Invest. 2019;129:4609–4628.
110. Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol
Aspects Med. 2018;62:75–88.
111. De Nola R, Menga A, Castegna A, Loizzi V, Ranieri G, Cicinelli E, et al. The crowded
crosstalk between cancer cells and stromal microenvironment in gynecological malig-
nancies
: Biological pathways and therapeutic implication. Int J Mol Sci. 2019;20:2401.
112. Erdogan B, Ao M, White LM, Means AL, Brewer BM, Yang L, et al. Cancer-associated
broblasts promote directional cancer cell migration by aligning bronectin. J Cell
Biol. 2017;216:3799–3816.
113. Li J, Zhi X, Sun Y, Chen M, Yao L. The PDGF family is associated with activated
tumor stroma and poor prognosis in ovarian cancer. Dis Markers. 2022;2022:5940049.
70 The Dynamics of Tumor Microenvironment and Therapeutic Targets
114. Yuzawa S, Kano MR, Einama T, Nishihara H. PDGFRβ expression in tumor
stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Med Oncol.
2012;29:2824–2830.
115. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in
the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med.
20 08;5
:e19.
116. Haubeiss S, Schmid JO, Mürdter TE, Sonnenberg M, Friedel G, van der Kuip H, et al.
Dasatinib reverses cancer-associated broblasts (CAFs) from primary lung carci-
nomas to a p
henotype comparable to that of normal broblasts. Mol Cancer. 2010;
9:1– 8.
117. Schmidt-Hansen B, Klingelhöfer J, Grum-Schwensen B, Christensen A, Andresen S,
Kruse C, et al. Functional signicance of metastasis-inducing S100A4 (Mts1) in tumor-
stroma interplay. J Biol Chem. 2004;279:24498–24504.
118. Cabezón T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, et al.
Expression of S100A4 by a variety of cell types present in the tumor microenvironment
of human breast cancer. Int J Cancer. 2007;121:1433–1444.
119. Schmidt-Hansen B, Örnås D, Grigorian M, Klingelhöfer J, Tulchinsky E, Lukanidin
E, et al. Extracellular S100A4 (mts1) stimulates invasive growth of mouse endothe-
lial cel
ls and modulates MMP-13 matrix metalloproteinase activity. Oncogene.
2004;23:5487–5495.
120. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and
dissemination precede pancreatic tumor formation. Cell. 2012;148:349–361.
121. Zhang X, Dong M, Pan Y, Chen J, Huang X, Jin Y, et al. Expression pattern of can-
cer-associated broblast and its clinical relevance in intrahepatic cholangiocarcinoma.
Hum Pathol. 2017;65:92–100.
122. Mundim FGL, Pasini FS, Nonogaki S, Rocha RM, Soares FA, Brentani MM, et al.
Breast carcinoma–associated broblasts share similar biomarker proles in matched
lymph node metastasis. Appl Immunohistochem Mol Morphol. 2016;24:712–720.
123. Jenkinson SR, Barraclough R, West CR, Rudland PS. S100A4 regulates cell motil-
ity and invasion in an in vitro model for breast cancer metastasis. Br J Cancer.
2004;90:253–262.
124. Grum-Schwensen B, Klingelhöfer J, Grigorian M, Almholt K, Nielsen BS, Lukanidin
E, et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a
T-cell d
eciency in primary tumors. Cancer Res. 2010;70:936–947.
125. Klingelhöfer J, Grum-Schwensen B, Beck MK, Knudsen RSP, Grigorian M, Lukanidin
E, et al. Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell
invasi
on. Neoplasia. 2012;14:1260-IN47.
126. Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M,
et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–
stroma crosstalk. Proc Natl Acad Sci. 2018;115:E3769–E3778.
127. Goicoechea SM, Garcia-Mata R, Staub J, Valdivia A, Sharek L, McCulloch CG, et al.
Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia forma-
tion in cancer-associated broblasts. Oncogene. 2014;33:1265–1273.
128. Cannon AR, Owen MK, Guerrero MS, Kerber ML, Goicoechea SM, Hemstreet
KC, et al. Palladin expression is a conserved characteristic of the desmoplastic
tumor mi
croenvironment and contributes to altered gene expression. Cytoskeleton.
2015;72:402– 411.
129. Alexander JI, Vendramini-Costa DB, Francescone R, Luong T, Franco-Barraza J, Shah
N, et al. Palladin isoforms 3 and 4 regulate cancer-associated broblast pro-tumor func-
tions in pa
ncreatic ductal adenocarcinoma. Sci Rep. 2021;11:3802.
130. Chin YR, Toker A. The actin-bundling protein palladin is an Akt1-specic substrate
that regulates breast cancer cell migration. Mol Cell. 2010;38:333–344.
71Cancer-Associated Fibroblasts and Glioblastoma
131. Lee K-W, Yeo S-Y, Sung CO, Kim S-H. Twist1 is a key regulator of cancer-associated
broblasts. Cancer Res. 2015;75:73–85.
132. Grzegrzolka J, Wojtyra P, Biala M, Piotrowska A, Gomulkiewicz A, Rys J, et al.
Correlation between expression of twist and podoplanin in ductal breast carcinoma.
Anticancer Res. 2017;37:5485–5493.
133. García-Palmero I, Torres S, Bartolomé RA, Peláez-García A, Larriba MJ, Lopez-
Lucendo M, et al. Twist1-induced activation of human broblasts promotes matrix stiff-
ness by upregulating palladin and collagen α1 (VI). Oncogene. 2016;35:5224–5236.
134. Zhang W, Bouchard G, Yu A, Shaq M, Jamali M, Shrager JB, et al. GFPT2-expressing
cancer-associated broblasts mediate metabolic reprogramming in human lung adeno-
carcinoma. Cancer Res. 2018;78:3445–3457.
135. Hanover JA, Chen W, Bond MR. O-GlcNAc in cancer: An oncometabolism-fueled
vicious cycle. J Bioenerg Biomembr. 2018;50:155–173.
136. de Queiroz RM, Carvalho É, Dias WB. O-GlcNAcylation: The sweet side of the cancer.
Front Oncol. 2014;4:132.
137. Akella NM, Ciraku L, Reginato MJ. Fueling the re: Emerging role of the hexosamine
biosynthetic pathway in cancer. BMC Biol. 2019;17:1–14.
138. Slawson C, Copeland RJ, Hart GW. O-GlcNAc signaling: Ametabolic link between
diabetes and cancer? Trends Biochem Sci. 2010;35:547–555.
139. Olivier-Van Stichelen S, Guinez C, Mir A-M, Perez-Cervera Y, Liu C, Michalski
J-C, et al. The hexosamine biosynthetic pathway and O-GlcNAcylation drive the
expression of β-catenin and cell proliferation. Am J Physiol Metab. 2012;302:
E417–E424.
140. Vasconcelos-dos-Santos A, Oliveira IA, Lucena MC, Mantuano NR, Whelan SA, Dias
WB, et al. Biosynthetic machinery involved in aberrant glycosylation: Promising tar-
gets for developing of drugs against cancer. Front Oncol. 2015;5:138.
141. Ding X, Liu H, Yuan Y, Zhong Q, Zhong X. Roles of GFPT2 expression lev-
els on the prognosis and tumor microenvironment of colon cancer. Front Oncol.
20 22;12:811559.
142. Huang Y, Wang H-C, Zhao J, Wu M-H, Shih T-C. Immunosuppressive roles of
galectin-1 in the tumor microenvironment. Biomolecules. 2021;11:1398.
143. Martínez-Bosch N, Navarro P. Targeting galectin-1 in pancreatic cancer: Immune sur-
veillance on guard. Oncoimmunology. 2014;3:e952201.
144. Jung E, Moon H, Cho BI, Jeong C, Joo Y, Lee Y, et al. Galectin-1 expression in cancer-
associated stromal cells correlates tumor invasiveness and tumor progression in breast
cancer. I
nt J Cancer. 2007;120:2331–2338.
145. Ngan CY, Yamamoto H, Seshimo I, Tsujino T, Man-i M, Ikeda JI, et al. Quantitative
evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer.
20 07;96:986 –992.
146. Otsuki S, Inokuchi M, Enjoji M, Ishikawa T, Takagi Y, Kato K, et al. Vimentin expres-
sion is associated with decreased survival in gastric cancer. Oncol Rep. 2011;25:
1235–1242.
147. Fang T, Zhang L, Yin X, Wang Y, Zhang X, Bian X, et al. The prognostic marker elastin
correlates with epithelial–mesenchymal transition and vimentin-positive broblasts in
gastric cancer. J Pathol Clin Res. 2023;9:56–72.
148. Maehira H, Miyake T, Iida H, Tokuda A, Mori H, Yasukawa D, et al. Vimentin
expression in tumor microenvironment predicts survival in pancreatic ductal ade-
nocarcinoma: Heterogeneity in broblast population. Ann Surg Oncol. 2019;26:
4791– 4804.
149. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions
in axon regeneration, apoptosis, adhesion, migration, cancer, and brosis. FASEB J.
2006;20:1045 –1054.
72 The Dynamics of Tumor Microenvironment and Therapeutic Targets
150. Zhu J, Thakolwiboon S, Liu X, Zhang M, Lubman DM. Overexpression of CD90
(Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment. PLoS
One. 2014;9:e115507.
151. Huynh PT, Beswick EJ, Coronado YA, Johnson P, O’Connell MR, Watts T, et al. CD
90+ stromal cells are the major source of IL-6, which supports cancer stem-like cells
and ina
mmation in colorectal cancer. Int J Cancer. 2016;138:1971–1981.
152. Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N,
et al. Thy-1+ cancer-associated broblasts adversely impact lung cancer prognosis. Sci
Rep. 2017;7:6478.
153. True LD, Zhang H, Ye M, Huang C-Y, Nelson PS, Von Haller PD, et al. CD90/THY1
is overexpressed in prostate cancer-associated broblasts and could serve as a cancer
biomarker. Mod Pathol. 2010;23:1346–1356.
154. Kamarudin NA, Abd Shukor N, Farouk WI, Hanapi NAM, Mohammed F. Stromal
expression of CD10 in invasive breast carcinoma and its association with tumour stage,
grade, E
R, PR and HER2 status. Malay J Pathol. 2021;43:389–396.
155. Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and
stroma of human breast cancer and its prognostic signicance. Clin Cancer Res an Off
J Am Assoc C
ancer Res. 1995;1:1035–1041.
156. Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschörner I, Rogatsch H, et al. Prognostic
signicance of tenascin-C expression in supercial and invasive bladder cancer. J Clin
Pathol. 2004;57:927–931.
157. Yorozu A, Yamamoto E, Niinuma T, Tsuyada A, Maruyama R, Kitajima H, et al.
Upregulation of adipocyte enhancer-binding protein 1 in endothelial cells promotes
tumor an
giogenesis in colorectal cancer. Cancer Sci. 2020;111:1631–1644.
158. Li D, Liu Z, Ding X, Qin Z. AEBP1 is one of the epithelial-mesenchymal transition
regulatory genes in colon adenocarcinoma. Biomed Res Int. 2021;2021:3108933.
159. Majdalawieh AF, Massri M, Ro H-S. AEBP1 is a novel oncogene: Mechanisms of
action and signaling pathways. J Oncol. 2020;2020:8097872.
160. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and
toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723–749.
161. Weber GF, Ashkar S, Cantor H. Interaction between CD44 and osteopontin as a poten-
tial basis for metastasis formation. Proc Assoc Am Physicians. 1997;109:1–9.
162. Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: Potential clini-
cal applications in cancer. Int J Mol Med. 2017;39:1327–1337.
163. Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, et al. The role of osteopontin in the
progression of solid organ tumour. Cell Death Dis. 2018;9:1–15.
164. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, et al. Osteopontin
induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J
Exp Clin Cancer Res. 2012;31:1–12.
165. Nagasawa A, Kubota R, Imamura Y, Nagamine K, Wang Y, Asakawa S, et al. Cloning
of the cDNA for a new member of the immunoglobulin superfamily (ISLR) containing
leucine-
rich repeat (LRR). Genomics. 1997;44:273–279.
166. Maeda K, Enomoto A, Hara A, Asai N, Kobayashi T, Horinouchi A, et al.
Identication of mein as a potential marker for mesenchymal stromal cells. Sci
Rep. 2016;6:22288.
167. Takahashi M, Kobayashi H, Mizutani Y, Hara A, Iida T, Miyai Y, et al. Roles of the
mesenchymal stromal/stem cell marker Mein/Islr in cancer brosis. Front Cell Dev
Biol. 2021;9:749924.
168. Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, et al. Mein-
positive cancer-associated broblasts inhibit pancreatic carcinogenesis. Cancer Res.
2019;79:5367–5381.
169. Hara A, Kobayashi H, Asai N, Saito S, Higuchi T, Kato K, et al. Roles of the mesen-
chymal stromal/stem cell marker mein in cardiac tissue repair and the development of
diastolic dysfunction. Circ Res. 2019;125:414–430.
73Cancer-Associated Fibroblasts and Glioblastoma
170. Minatoguchi S, Saito S, Furuhashi K, Sawa Y, Okazaki M, Shimamura Y, et al. A novel
renal perivascular mesenchymal cell subset gives rise to broblasts distinct from classic
myobroblasts. Sci Rep. 2022;12:5389.
171. Nakahara Y, Hashimoto N, Sakamoto K, Enomoto A, Adams TS, Yokoi T, et al.
Fibroblasts positive for mein have anti-brotic properties in pulmonary brosis. Eur
Respir J. 2
021;58.
172. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7
counteracts TGF-β1–induc
ed epithelial-to-mesenchymal transition and reverses chronic
renal injury. Nat Med. 2003;9:964–968.
173. Kobayashi H, Gieniec KA, Wright JA, Wang T, Asai N, Mizutani Y, et al. The balance
of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogen-
esis. Gastroenterology. 2021;160:1224–1239.
174. Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, et al. Pharmacologic
conversion of cancer-associated broblasts from a protumor phenotype to an antitu-
mor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics.
Oncogene. 2022;41:2764–2777.
175. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat
Rev Cancer. 2012;12:540–552.
176. Mizutani Y, Iida T, Ohno E, Ishikawa T, Kinoshita F, Kuwatsuka Y, et al. Safety and
efcacy of MIKE-1 in patients with advanced pancreatic cancer: Astudy protocol for
an open-label phase I/II investigator-initiated clinical trial based on a drug reposition-
ing approach that reprograms the tumour stroma. BMC Cancer. 2022;22:205.
177. Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan A-C,
et al. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen.
Clin Canc
er Res. 2017;23:1710–1721.
178. Zheng B, Ohuchida K, Chijiiwa Y, Zhao M, Mizuuchi Y, Cui L, et al. CD146 attenu-
ation in cancer-associated broblasts promotes pancreatic cancer progression. Mol
Carcinog. 2016;55:1560–1572.
179. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman
JN, Chiavarina B, et al. Tumor cells induce the cancer associated broblast pheno-
type via
caveolin-1 degradation: Implications for breast cancer and DCIS therapy with
autophagy inhibitors. Cell Cycle. 2010;9:2423–2433.
180. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal
cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 2009;174:
2035–2043.
181. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence
of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical out-
come in human breast cancers. Am J Pathol. 2009;174:2023–2034.
182. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence
of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease
spread a
nd epithelial Akt activation. Cell Cycle. 2009;8:2420–2424.
183. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP.
Caveolin-1 and cancer metabolism in the tumor microenvironment: Markers, models,
and mechanisms. Annu Rev Pathol Mech Dis. 2012;7:423–467.
184. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated broblasts
transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin
Cancer Biol. 2014;25:47–60, Elsevier.
185. Sazeides C, Le A. Metabolic relationship between cancer-associated broblasts and
cancer cells. Heterog Cancer Metab. 2018:149–165.
186. Thompson T C, Tahi r SA, Li L , Watana be M, Naruishi K, Yang G, et al. The role of caveolin-1
in prostate cancer: Clinical implications. Prostate Cancer Prostatic Dis. 2010;13:6–11.
187. Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, et al.
Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors
tumor invasion and metastasis. Cell. 2011;146:148–163.
74 The Dynamics of Tumor Microenvironment and Therapeutic Targets
188. Yamao T, Yamashita Y, Yamamura K, Nakao Y, Tsukamoto M, Nakagawa S, et al.
Cellular senescence, represented by expression of caveolin-1, in cancer-associated
brobl
asts promotes tumor invasion in pancreatic cancer. Ann Surg Oncol. 2019;26:
1552–1559.
189. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribu-
tion of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in
humans. I m munology. 2001;102:173–179.
190. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, et al. Down-
regulation of the macrophage lineage through interaction with OX2 (CD200). Science
(80–). 2
000;290:1768–1771.
191. Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, et al. CD200-
positive cancer associated broblasts augment the sensitivity of epidermal growth factor
receptor mutation-positive lung adenocarcinomas to EGFR tyrosine kinase inhibitors.
Sci Rep. 2017;7:46662.
192. MacNeil T, Vathiotis IA, Sha S, Aung TN, Zugazagoitia J, Gruver AM, et al. Multiplex
quantitative analysis of tumor-inltrating lymphocytes, cancer-associated broblasts,
and CD20
0 in pancreatic cancer. Cancers (Basel). 2021;13:5501.
193. Mahadevan D, Lanasa MC, Farber C, Pandey M, Whelden M, Faas SJ, et al. Phase
I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma:
Blocka
de of the immune checkpoint CD200. J Immunother Cancer. 2019;7:1–13.
194. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, et al. Podoplanin-positive
broblasts enhance lung adenocarcinoma tumor formation: Podoplanin in broblast
functions for tumor progression. Cancer Res. 2011;71:4769–4779.
195. Breiteneder-Geleff S, Soleiman A, Horvat R, Amann G, Kowalski H, Kerjaschki D.
Podoplanin—a specic marker for lymphatic endothelium expressed in angiosarcoma.
Verh Dts
ch Ges Pathol. 1999;83:270–275.
196. Neri S, Ishii G, Hashimoto H, Kuwata T, Nagai K, Date H, et al. Podoplanin-expressing
cancer-associated broblasts lead and enhance the local invasion of cancer cells in lung
adenoc
arcinoma. Int J Cancer. 2015;137:784–796.
197. Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, et al. Podoplanin-positive
cancer-associated broblasts in the tumor microenvironment induce primary resis-
tance to EG
FR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res.
2015;21:6 42–651.
198. Ito S, Ishii G, Hoshino A, Hashimoto H, Neri S, Kuwata T, et al. Tumor promoting effect
of podoplanin-positive broblasts is mediated by enhanced RhoA activity. Biochem
Biophys Res Commun. 2012;422:194–199.
199. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J
Cancer. 2007;96:1–5.
200. Sakai T, Aokage K, Neri S, Nakamura H, Nomura S, Tane K, et al. Link between tumor-
promoting brous microenvironment and an immunosuppressive microenvironment in
stage Ilung adenocarcinoma. Lung Cancer. 2018;126:64–71.
201. Suzuki J, Aokage K, Neri S, Sakai T, Hashimoto H, Su Y, et al. Relationship between
podoplanin-expressing cancer-associated broblasts and the immune microenviron-
ment of ea
rly lung squamous cell carcinoma. Lung Cancer. 2021;153:1–10.
202. Cai D, Wu X, Hong T, Mao Y, Ge X, Hua D. CD61+ and CAF+ were found to be
good prognosis factors for invasive breast cancer patients. Pathol Pract. 2017;213:
1296–1301.
203. Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, et al.
Podoplanin expression identied in stromal broblasts as a favorable prognostic marker
in patients with colorectal carcinoma. Oncology. 2009;77:53–62.
75Cancer-Associated Fibroblasts and Glioblastoma
204. Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-
species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-
presenting cancer-associated broblasts. Cancer Discov. 2019;9:1102–1123.
205. Jacobs J, Deschoolmeester V, Zwaenepoel K, Flieswasser T, Deben C, Van den Bossche
J, et al. Unveiling a CD70-positive subset of cancer-associated broblasts marked by
pro-mi
gratory activity and thriving regulatory T cell accumulation. Oncoimmunology.
2018;7:e1440167.
206. Jia D, Liu Z, Deng N, Tan TZ, Huang RY-J, Taylor-Harding B, et al. A COL11A1-
correlated pan-cancer gene signature of activated broblasts for the prioritization of
therap
eutic targets. Cancer Lett. 2016;382:203–214.
207. Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, et al.
LRRC15+ myobroblasts dictate the stromal setpoint to suppress tumour immunity.
Nature.
2022;611:148–154.
208. Santi A, Kugeratski FG, Zanivan S. Cancer associated broblasts: The architects of
stroma remodeling. Proteomics. 2018;18:1700167.
209. Bif G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK/STAT
signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal
adenocarcinoma. Cancer Discov. 2019;9:282–301.
210. Wörmann SM, Song L, Ai J, Diakopoulos KN, Kurkowski MU, Görgülü K, et al. Loss
of P53 function activates JAK2–STAT3 signaling to promote pancreatic tumor growth,
stroma m
odication, and gemcitabine resistance in mice and is associated with patient
survival. Gastroenterology. 2016;151:180–193.
211. Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, et al. CAF hierarchy
driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant
environ
ment via perlecan. Nat Commun. 2019;10:3637.
212. Lawrence MG, Pidsley R, Niranjan B, Papargiris M, Pereira BA, Richards M, et al.
Alterations in the methylome of the stromal tumour microenvironment signal the pres-
ence and severity of prostate cancer. Clin Epigenetics. 2020;12:1–18.
213. Pidsley R, Lawrence MG, Zotenko E, Niranjan B, Statham A, Song J, et al. Enduring epi-
genetic landmarks dene the cancer microenvironment. Genome Res. 2018;28:625–638.
214. Lee YT, Tan YJ, Falasca M, Oon CE. Cancer-associated broblasts: Epigenetic regula-
tion and therapeutic intervention in breast cancer. Cancers (Basel). 2020;12:2949.
215. Ippolito L, Comito G, Parri M, Iozzo M, Duatti A, Virgilio F, et al. Lactate rewires lipid
metabolism and sustains a metabolic–epigenetic axis in prostate cancer. Cancer Res.
2022;8
2:1267–1282.
216. Xiao Q, Zhou D, Rucki AA, Williams J, Zhou J, Mo G, et al. Cancer-associated bro-
blasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic
DNA methylation. Cancer Res. 2016;76:5395–5404.
217. Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, et al.
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated bro-
blasts. Nature. 2019;569:723–728.
218. Pan X, Zhou J, Xiao Q, Fujiwara K, Zhang M, Mo G, et al. Cancer-associated broblast
heterogeneity is associated with organ-specic metastasis in pancreatic ductal adeno-
carcin
oma. J Hematol Oncol. 2021;14:1–6.
219. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK,
Frank PG, et al. The reverse Warburg effect: Aerobic glycolysis in cancer associated
brobl
asts and the tumor stroma. Cell Cycle. 2009;8:3984–4001.
220. Becker LM, O’Connell JT, Vo AP, Cain MP, Tampe D, Bizarro L, et al. Epigenetic
reprogramming of cancer-associated broblasts deregulates glucose metabolism and
facilitates progression of breast cancer. Cell Rep. 2020;31.